BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10225988)

  • 1. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies.
    Todeschini G; Franchini M; Tecchio C; Meneghini V; Pizzolo G; Veneri D; Murari C; Ricetti MM; Perona G
    Int J Infect Dis; 1998-1999 Winter; 3(2):99-104. PubMed ID: 10225988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
    Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
    BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours.
    Marin M; Gudiol C; Ardanuy C; Garcia-Vidal C; Calvo M; Arnan M; Carratalà J
    J Infect; 2014 Nov; 69(5):417-23. PubMed ID: 24960295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes.
    Chatzinikolaou I; Abi-Said D; Bodey GP; Rolston KV; Tarrand JJ; Samonis G
    Arch Intern Med; 2000 Feb; 160(4):501-9. PubMed ID: 10695690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of neutropenia on the clinical outcomes of Staphylococcus aureus bacteremia in patients with hematologic malignancies: a 10-year experience in a tertiary care hospital.
    Ryu BH; Lee SC; Kim M; Eom Y; Jung J; Kim MJ; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Woo JH; Kim YS; Chong YP
    Eur J Clin Microbiol Infect Dis; 2020 May; 39(5):937-943. PubMed ID: 31925572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies.
    Micozzi A; Venditti M; Monaco M; Friedrich A; Taglietti F; Santilli S; Martino P
    Clin Infect Dis; 2000 Sep; 31(3):705-11. PubMed ID: 11017819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies.
    Trecarichi EM; Tumbarello M; Caira M; Candoni A; Cattaneo C; Pastore D; Fanci R; Nosari A; Vianelli N; Busca A; Spadea A; Pagano L
    Haematologica; 2011 Jan; 96(1):e1-3; author reply e4. PubMed ID: 21193424
    [No Abstract]   [Full Text] [Related]  

  • 8. High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations.
    Chumbita M; Puerta-Alcalde P; Yáñez L; Angeles Cuesta M; Chinea A; Español-Morales I; Fernandez-Abellán P; Gudiol C; González-Sierra P; Rojas R; Sánchez-Pina JM; Vadillo IS; Sánchez M; Varela R; Vázquez L; Guerreiro M; Monzo P; Lopera C; Aiello TF; Peyrony O; Soriano A; Garcia-Vidal C
    Microbiol Spectr; 2023 Aug; 11(4):e0067423. PubMed ID: 37367629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s.
    Maschmeyer G; Braveny I
    Eur J Clin Microbiol Infect Dis; 2000 Dec; 19(12):915-25. PubMed ID: 11205628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection.
    Fernández-Cruz A; Alba N; Semiglia-Chong MA; Padilla B; Rodríguez-Macías G; Kwon M; Cercenado E; Chamorro-de-Vega E; Machado M; Pérez-Lago L; García de Viedma D; Díez Martín JL; Muñoz P
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of hospitalized neutropenic oncology patients with Pseudomonas aeruginosa bloodstream infections: focus on oral fluoroquinolone conversion.
    Yan LZ; Herrington JD
    J Oncol Pharm Pract; 2016 Aug; 22(4):584-90. PubMed ID: 26156260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.
    Lee JY; Kang CI; Ko JH; Lee WJ; Seok HR; Park GE; Cho SY; Ha YE; Chung DR; Lee NY; Peck KR; Song JH
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6673-6678. PubMed ID: 27572416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study.
    Vuotto F; Berthon C; Lemaitre N; Duhamel A; Balkaran S; Le Ray E; Micol JB; Faure K; Alfandari S
    Am J Infect Control; 2013 Jun; 41(6):527-30. PubMed ID: 23219670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.
    Gudiol C; Albasanz-Puig A; Laporte-Amargós J; Pallarès N; Mussetti A; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo M; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Paz Morales H; Brunel AS; García E; Isler B; Kern WV; Morales I; Maestro-de la Calle G; Montero M; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmatti P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Carratalà J;
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies.
    Chong Y; Yakushiji H; Ito Y; Kamimura T
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e171-5. PubMed ID: 20471883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
    Albasanz-Puig A; Gudiol C; Parody R; Tebe C; Akova M; Araos R; Bote A; Brunel AS; Calik S; Drgona L; García E; Hemmati P; Herrera F; Ibrahim KY; Isler B; Kanj S; Kern W; Maestro de la Calle G; Manzur A; Marin JI; Márquez-Gómez I; Martín-Dávila P; Mikulska M; Montejo JM; Montero M; Morales HMP; Morales I; Novo A; Oltolini C; Peghin M; Del Pozo JL; Puerta-Alcalde P; Ruiz-Camps I; Sipahi OR; Tilley R; Yáñez L; Gomes MZR; Carratalà J;
    BMJ Open; 2019 May; 9(5):e025744. PubMed ID: 31129580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer.
    González-Barca E; Carratalà J; Mykietiuk A; Fernández-Sevilla A; Gudiol F
    Eur J Clin Microbiol Infect Dis; 2001 Feb; 20(2):117-9. PubMed ID: 11305464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteremia in hematological and oncological children with febrile neutropenia: experience in a tertiary medical center in Taiwan.
    Lai HP; Hsueh PR; Chen YC; Lee PI; Lu CY; Lu MY; Lin WC; Hsieh YC; Lee CY; Lin KH; Huang LM
    J Microbiol Immunol Infect; 2003 Sep; 36(3):197-202. PubMed ID: 14582565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors of septic shock in patients with hematologic malignancies and Pseudomonas infections.
    Jeddi R; Ghédira H; Ben Amor R; Turki A; Kacem K; Ben Abdennebi Y; Ben Lakhal R; Aissaoui L; Ben Abid H; Bel Hadjali Z; Meddeb B
    Hematology; 2011 May; 16(3):160-5. PubMed ID: 21669056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes.
    Vidal F; Mensa J; Almela M; Martínez JA; Marco F; Casals C; Gatell JM; Soriano E; Jimenez de Anta MT
    Arch Intern Med; 1996 Oct; 156(18):2121-6. PubMed ID: 8862105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.